BR112016003142A2 - ligação de polipeptídeos estáveis ao c5 do complemento humano - Google Patents

ligação de polipeptídeos estáveis ao c5 do complemento humano

Info

Publication number
BR112016003142A2
BR112016003142A2 BR112016003142A BR112016003142A BR112016003142A2 BR 112016003142 A2 BR112016003142 A2 BR 112016003142A2 BR 112016003142 A BR112016003142 A BR 112016003142A BR 112016003142 A BR112016003142 A BR 112016003142A BR 112016003142 A2 BR112016003142 A2 BR 112016003142A2
Authority
BR
Brazil
Prior art keywords
binding
human complement
stable polypeptides
polypeptides
stable
Prior art date
Application number
BR112016003142A
Other languages
English (en)
Portuguese (pt)
Inventor
Nordling Erik
Nilsson Joakim
Strömberg Patrik
Original Assignee
Swedish Orphan Biovitrum Ab Publ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Swedish Orphan Biovitrum Ab Publ filed Critical Swedish Orphan Biovitrum Ab Publ
Priority to BR122023020080-2A priority Critical patent/BR122023020080B1/pt
Publication of BR112016003142A2 publication Critical patent/BR112016003142A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
BR112016003142A 2013-08-28 2014-08-28 ligação de polipeptídeos estáveis ao c5 do complemento humano BR112016003142A2 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122023020080-2A BR122023020080B1 (pt) 2013-08-28 2014-08-28 Polipeptídeos e compostos de ligação a c5 do complemento humano

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1350986 2013-08-28
PCT/EP2014/068282 WO2015028558A1 (en) 2013-08-28 2014-08-28 Stable polypeptides binding to human complement c5

Publications (1)

Publication Number Publication Date
BR112016003142A2 true BR112016003142A2 (pt) 2017-10-17

Family

ID=51539238

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016003142A BR112016003142A2 (pt) 2013-08-28 2014-08-28 ligação de polipeptídeos estáveis ao c5 do complemento humano

Country Status (29)

Country Link
US (1) US9994626B2 (https=)
EP (2) EP3038633B1 (https=)
JP (2) JP6767865B2 (https=)
KR (1) KR102446636B1 (https=)
CN (1) CN105658228B (https=)
AU (1) AU2014314222B2 (https=)
BR (1) BR112016003142A2 (https=)
CA (1) CA2926976C (https=)
CY (1) CY1123732T1 (https=)
DK (1) DK3038633T3 (https=)
ES (1) ES2842105T3 (https=)
HR (1) HRP20210013T1 (https=)
HU (1) HUE052613T2 (https=)
IL (1) IL244218A (https=)
LT (1) LT3038633T (https=)
MX (1) MX382140B (https=)
MY (1) MY173804A (https=)
NZ (1) NZ718153A (https=)
PH (1) PH12016500371B1 (https=)
PL (1) PL3038633T3 (https=)
PT (1) PT3038633T (https=)
RS (1) RS61347B1 (https=)
RU (2) RU2020128977A (https=)
SA (1) SA516370622B1 (https=)
SG (1) SG11201602679VA (https=)
SI (1) SI3038633T1 (https=)
SM (1) SMT202100006T1 (https=)
UA (1) UA117933C2 (https=)
WO (1) WO2015028558A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013126006A1 (en) * 2012-02-20 2013-08-29 Swedish Orphan Biovitrum Ab (Publ) Polypeptides binding to human complement c5
MX367423B (es) 2013-08-28 2019-08-21 Affibody Ab Polipeptidos de union a c5.
CN105658228B (zh) * 2013-08-28 2020-02-07 瑞典孤儿比奥维特鲁姆有限公司 结合人类补体c5的稳定多肽
UY37651A (es) * 2017-03-31 2018-10-31 Swedish Orphan Biovitrum Ab Publ Polipéptido de unión al il-1r-i
BR112019028269A2 (pt) 2017-07-11 2020-07-14 Alexion Pharmaceuticals, Inc. polipeptídeos que se ligam ao componente c5 do complemento ou à albumina sérica e suas proteínas de fusão
JP2024506070A (ja) * 2021-02-15 2024-02-08 アフィボディ アクティエボラーグ 新規ｈｅｒ２結合ポリペプチド
CA3237246A1 (en) * 2021-11-01 2023-05-04 Ipc Research, Llc Administration of c5-binding proteins
WO2024227886A1 (en) 2023-05-02 2024-11-07 Mebrahtu Aman Bispecific binding molecule

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
AU2001296594A1 (en) 2000-10-10 2002-04-22 Tanox, Inc. Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
BRPI0211953B8 (pt) * 2001-08-17 2021-05-25 Genentech Inc anticorpo monoclonal ou fragmento de ligação a antígeno que se liga a c5 e c5a sem a prevenção da formação de c5b, linhagem celular, composição farmacêutica, bem como método in vitro para inibir a atividade de c5a e método de diagnóstico in vitro
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
WO2005023866A2 (en) 2003-09-10 2005-03-17 Baxter International Inc. Peptides that inhibit complement activation
SE0400274D0 (sv) * 2004-02-09 2004-02-09 Affibody Ab New polypeptide
GB0518443D0 (en) * 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
KR101584468B1 (ko) * 2006-03-08 2016-01-13 아케믹스 엘엘씨 안질환의 치료에 유용한 보체 결합 앱타머 및 항-ｃ5 제제
PL3167888T3 (pl) 2006-03-15 2024-08-26 Alexion Pharmaceuticals, Inc. Leczenie pacjentów z napadową nocną hemoglobinurią za pomocą inhibitora dopełniacza
CA2694139C (en) 2007-07-31 2018-06-05 Affibody Ab Albumin binding polypeptide compositions
DK2231860T3 (da) * 2007-12-19 2011-12-05 Affibody Ab Polypeptid afledt protein A og i stand til at binde PDGF
US9187535B2 (en) 2007-12-19 2015-11-17 Affibody Ab Polypeptide derived from protein A and able to bind PDGF
EP2072525A1 (en) 2007-12-21 2009-06-24 Affibody AB New polypeptides having affinity for HER2
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
MX2013000314A (es) 2010-07-09 2013-01-29 Affibody Ab Polipeptidos.
WO2013126006A1 (en) 2012-02-20 2013-08-29 Swedish Orphan Biovitrum Ab (Publ) Polypeptides binding to human complement c5
JP5980104B2 (ja) 2012-11-22 2016-08-31 三菱電機株式会社 液晶表示装置の製造方法および液晶表示装置の製造システム
EP2935335B1 (en) 2012-12-19 2020-10-28 Affibody AB New polypeptides
MX367423B (es) 2013-08-28 2019-08-21 Affibody Ab Polipeptidos de union a c5.
CN105658228B (zh) * 2013-08-28 2020-02-07 瑞典孤儿比奥维特鲁姆有限公司 结合人类补体c5的稳定多肽

Also Published As

Publication number Publication date
HRP20210013T1 (hr) 2021-04-02
WO2015028558A1 (en) 2015-03-05
IL244218A (en) 2017-11-30
EP3811961A1 (en) 2021-04-28
PL3038633T3 (pl) 2021-07-19
RS61347B1 (sr) 2021-02-26
UA117933C2 (uk) 2018-10-25
KR20160048121A (ko) 2016-05-03
IL244218A0 (en) 2016-04-21
US9994626B2 (en) 2018-06-12
PH12016500371A1 (en) 2016-05-02
MY173804A (en) 2020-02-24
NZ718153A (en) 2022-05-27
PH12016500371B1 (en) 2016-05-02
KR102446636B1 (ko) 2022-09-23
MX2016002397A (es) 2016-09-08
JP2016529270A (ja) 2016-09-23
SG11201602679VA (en) 2016-05-30
CN105658228A (zh) 2016-06-08
EP3811961B1 (en) 2025-08-20
AU2014314222A1 (en) 2016-04-21
RU2733897C2 (ru) 2020-10-09
CA2926976C (en) 2023-11-28
CA2926976A1 (en) 2015-03-05
HK1225656A1 (en) 2017-09-15
SI3038633T1 (sl) 2021-05-31
AU2014314222B2 (en) 2018-05-24
US20160311870A1 (en) 2016-10-27
SA516370622B1 (ar) 2018-12-23
EP3038633A1 (en) 2016-07-06
HUE052613T2 (hu) 2021-05-28
RU2020128977A (ru) 2021-11-30
DK3038633T3 (da) 2021-01-11
RU2016111115A (ru) 2017-10-03
BR122023020080A2 (pt) 2023-12-26
CN105658228B (zh) 2020-02-07
JP6767865B2 (ja) 2020-10-14
CY1123732T1 (el) 2021-10-29
MX382140B (es) 2025-03-13
EP3038633B1 (en) 2020-10-14
LT3038633T (lt) 2021-03-25
RU2016111115A3 (https=) 2018-04-25
PT3038633T (pt) 2021-01-14
JP2020172505A (ja) 2020-10-22
ES2842105T3 (es) 2021-07-12
SMT202100006T1 (it) 2021-03-15

Similar Documents

Publication Publication Date Title
BR112016003142A2 (pt) ligação de polipeptídeos estáveis ao c5 do complemento humano
CO2020009625A2 (es) Inhibidor de fap
MX2019003474A (es) Metodos mejorados para evaluar el estado de la proteina acidica fibrilar glial (gfap) en muestras de pacientes.
BR112017000671A2 (pt) moléculas com especificidade para cd79 e cd22
BR112016024494A2 (pt) análogos de peptídeo com sonda(s) de aminoácidos ramificados
BR112017023868A2 (pt) anticorpos anti-itga3, anticorpos anti-itga3 ativáveis, e métodos de uso dos mesmos
EA201591839A1 (ru) Терапевтические пептиды
BR112016014966A2 (pt) Anticorpos e fragmentos anti-vista
UA118558C2 (uk) Пептидна сполука
DOP2015000234A (es) COMPOSICIONES DE ARNi CONTRA EL COMPONENTE C5 DEL COMPLEMENTO Y METODOS PARA SU USO.
BR112015022191A8 (pt) compostos heteroarila e usos dos mesmos
NI201200080A (es) Antagonistas de il-17a
BR112016029582A2 (pt) derivados de exendina-4 como agonistas de receptor de glucagon seletivos
BR112015030385A8 (pt) composto, composto para uso e composição farmacêutica
CL2017000053A1 (es) Anticuerpos de unión a protofibrillas aß
BR112018013011A2 (pt) composições de alimento para animais de estimação
BR112018000632A2 (pt) moléculas de anticorpo que ligam a cd79
BR112016000565A2 (pt) polipeptídeo cíclico, derivado ou análogo do mesmo e seu uso modulador alostérico, composição farmacêutica, processo para produzir a mesma
BR112015017241A8 (pt) composto, composição farmacêutica, uso do composto e da composição farmacêutica e kit
MY188784A (en) Il-17a-binding polypeptides
MX2017009294A (es) Tratamiento de pacientes pediatricos con diabetes mellitus de tipo 2 con lixisenatida.
BR112015000917A2 (pt) método
EA201792124A1 (ru) Биотин для лечения амиотрофического латерального склероза
BR112018016198A2 (pt) compostos antagonistas do receptor de somatostatina e métodos de uso do mesmo
BR112018070547A2 (pt) agonistas de rara para o tratamento de aml e mds

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023020080-2 PROTOCOLO 870230086517 EM 02/10/2023 10:59.